Eli Lilly and Co. is buying a Waltham biotech in a deal valued at around $3.2 billion.
The startup being acquired is Morphic Holding Inc., a Waltham company working on treatments for chronic diseases such as types of inflammatory bowel disease.
WATCH ANYTIME FOR FREE
 |
Stream NBC10 Boston news for free, 24/7, wherever you are. |
Indianapolis-based Lilly plans to acquire all outstanding shares of Morphic for $57 per share in cash. The purchase price at closing is a premium of around 79% to the closing stock price on Friday.
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox. Sign up for our News Headlines newsletter.
